MARIA DEL PILAR ESTEVEZ DIZ
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/24 - Laboratório de Oncologia Experimental, Hospital das Clínicas, Faculdade de Medicina
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
- Carboplatin-based chemoradiotherapy in advanced cervical cancer: an alternative to cisplatin-based regimen?(2016) SEBASTIAO, Ana Morais; ROCHA, Lucila Soares da Silva; GIMENEZ, Rodrigo Darouche; BARROS, Laryssa Almeida Borges de; FUKUSHIMA, Julia Tizuko; SILVA, Samantha Cabral Severino da; MIRANDA, Vanessa da Costa; CAIRES, Inacelli Queiros de Souza; FREITAS, Daniela de; ABDO FILHO, Elias; DIZ, Maria Del Pilar EstevezObjective: To evaluate the results of treatment with cisplatin or carboplatin concomitant with radiotherapy (RT) in cases of locally advanced cervical cancer (CC). Methods: This study is a retrospective analysis of medical records of 184 patients with cervical cancer stage IIB-IVA who were treated at Instituto do Cancer do Estado de Sao Paulo from May 2008 to December 2012. All patients received complete pelvic region external-beam RT with weekly cisplatin (cis-RT, 40 mg/m(2); n = 159) or carboplatin (carbo-RT, AUC 2; n = 25), followed by high-dose-rate intracavitary brachytherapy (HDR-ICBT). Primary endpoint was progression free survival; secondary endpoints were overall survival and overall response rate, which includes complete and partial responses. Results: Five or more chemotherapy cycles were administered to 87.3% and 84% of the cis-RT- and carbo-RT- treated patients, respectively (p = 0.749). Estimated 3-years progression free survival was 59% in the cis-RT group vs 40% in the carbo-RT group (p = 0.249). Estimated 3-years overall survival was 70% in the cis-RT group vs 68% in the carbo-RT group (p = 0.298). Overall response rate (95.3% cis-RT vs 95.4% carbo-RT; p = 0.911) and grade >= 3 toxic effects (8.5% cis-RT vs 11.8% carbo-RT; p = 0.757) were similar. In multivariate analysis, only the overall response rate was a significant predictor of survival. Conclusions: Patients with advanced cervical cancer who are treated with carbo-RT have similar 3-years overall survival, progression free survival, overall response rate, and toxic effects when compared to cis-RT-treated patients. Carbo-RT may be an alternative treatment in patients that cannot receive cisplatin.
- Profile of cancer patients who visit a specialized emergency room in Sao Paulo, Brazil(2016) RAPOZO, M. M.; HATANAKA, V. M.; BERNARDES, M. C.; ALBUQUERQUE, G. M.; DIZ, M. D. P. E.
bookPart Estadiamento do câncer(2016) DIZ, Maria Del Pilar Estevez; CASTRIA, Tiago Biachi de- The role of platinum rechallenge as second line chemotherapy for metastatic endometrial carcinoma.(2016) SOUZA, Ronaldo Pereira; SOARES, Gregorio Pinheiro; LAGE, Liana Valente; FANELLI, Marcello Ferretti; SANCHES, Solange Moraes; GUIMARAES, Andrea Paiva G.; RIBEIRO, Adriana Regina G.; SAITO, Augusto; COSTA, Alexandre Andre Balieiro Anastacio da; ESTEVEZ-DIZ, Maria Del Pilar
conferenceObject EVALUATION OF AN INTEGRATED CARE PATHWAY FOR RECTAL CANCER TREATMENT IMPLEMENTATION USING A LOGIC MODEL(2016) KOBAYASHI, S. T.; CAMPOLINA, A. G.; SOAREZ, P. C.; JR, U. Ribeiro; DIZ, M. D.; HOFF, P. M.conferenceObject PREDICTABILITY OF BRCA1/2 MUTATION STATUS IN OVARIAN CANCER PATIENTS: HOW TO SELECT WOMEN FOR GENETIC TESTING IN MIDDLE-INCOME COUNTRIES?(2016) TEIXEIRA, N.; MAISTRO, S.; DIZ, M. D. P. E.; MOURITS, M. J. E.; OOSTERWIJK, J. C.; FOLGUEIRA, M. A. K.; BOCK, G. H. de- Hereditary cancer risk assessment: insights and perspectives for the Next-Generation Sequencing era(2016) GOMY, Israel; DIZ, Maria Del Pilar EstevezHereditary cancer risk assessment is a multidisciplinary and dynamic process, with the purpose of estimating probabilities of germline mutations in cancer susceptibility genes and assessing empiric risks of cancer based on personal and family histories, in order to offer clinical and molecular diagnoses and clinical management based on these risks. Genetic tests are available and most of them are reimbursed by insurance companies, although they are generally not covered by the public health systems of developing countries. More recently, molecular diagnosis of hereditary cancer is feasible through next-generation sequencing (NGS) panels. Here we review the benefits and limitations of NGS technologies in the clinical practice.
- Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil(2016) MAISTRO, Simone; TEIXEIRA, Natalia; ENCINAS, Giselly; KATAYAMA, Maria Lucia Hirata; NIEWIADONSKI, Vivian Dionisio Tavares; CABRAL, Larissa Garcia; RIBEIRO, Roberto Marques; GABURO JUNIOR, Nelson; GOUVEA, Ana Carolina Ribeiro Chaves de; CARRARO, Dirce Maria; SABINO, Ester Cerdeira; DIZ, Maria del Pilar Estevez; CHAMMAS, Roger; BOCK, Geertruida Hendrika de; FOLGUEIRA, Maria Aparecida Azevedo KoikeBackground: Approximately 8-15% epithelial ovarian cancer patients are BRCA1 or BRCA2 germline mutation carriers. Brazilian inhabitants may have peculiar genetic characteristics associated with ethnic diversity, and studies focusing on the entire BRCA1/BRCA2 gene sequencing in Brazilian ovarian cancer patients are still lacking. The aim of this study was to evaluate BRCA1/2 mutations, through entire gene sequencing, in a Brazilian population of women with epithelial ovarian cancer. Methods: In a cross sectional study performed in one reference centre for cancer treatment in Sao Paulo, Brazil, 100 patients diagnosed with epithelial ovarian cancer unselected for family history of breast and/or ovarian cancer were included. The complete coding sequence of BRCA1/2 genes was evaluated through Next-Generation or capillary sequencing. Large deletions were investigated through Multiplex Ligation-dependent Probe Amplification (MLPA). Results: Nineteen pathogenic mutations (BRCA1: n = 17 and BRCA2: n = 2) featuring 14 different mutations, including two large deletions in BRCA1 (exon 1-2 deleted and exon 5-7 deleted) were identified. Three mutations were detected more than once (c.3331_3334delCAAG, c.5266dupC and c.4484G > T). Two novel frameshift mutations were identified, one in BRCA1 (c.961_962delTG) and one in BRCA2 (c.1963_1963delC). BRCA1/2 mutations were seen in 35.5% of the patients with first and/or second-degree relatives with breast and/or ovarian cancer. Nineteen variants of uncertain significance (VUS) were detected (BRCA1: n = 2 and BRCA2: n = 17), including five distinct missense variants (BRCA1: c. 5348 T > C; BRCA2: c.2350A > G, c.3515C > T, c.7534C > T, and c.8351G > A). Conclusions: Among epithelial ovarian cancer patients unselected for family history of cancer, 19% were BRCA1/2 germline mutation carriers. Almost 3/4 of the BRCA mutations, including two large deletions, were detected only once. Our work emphasizes the need of entire gene sequencing and MLPA screening in Brazil.